A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab

<div>(a) Diurnal variations for blood ACTH and cortisol, and urinary cortisol indicated low levels. (b) Corticotropin-releasing hormone (CRH) stimulation testing showed no change in adrenocorticotropic hormone (ACTH) or cortisol level. The CRH stimulation test was conducted in the morning under a fasting condition.</div>

Case Reports in Endocrinology

fig2

Figure 2

Figure 2: A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab 

Figure 2 | A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab 